• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Treat NMD Logo (Copyright)

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us

Limb girdle muscular dystrophy

Home / Resources and Support / Neuromuscular Disease Information / Limb girdle muscular dystrophy

What is limb girdle muscular dystrophy?

Limb girdle muscular dystrophy (LGMD) is not a single condition but a number of different inherited muscular dystrophies that are grouped under the label ‘limb girdle’ because they generally affect the pelvic and shoulder girdles. The different types of LGMD have different features associated with them, however, the common feature of the disease is weakness in the muscles in the top part of the arms and shoulders and the hips and thighs. These muscles are often called the ‘proximal’ muscles because they are nearest to the body.

What is the cause of limb-girdle muscular dystrophy?

All forms of LGMD have a genetic basis and are caused by mutations in genes which are required for muscles to function properly. This leads to muscle weakness. The different forms of LGMD are divided into two main groups depending on how they are inherited: autosomal recessive (Type 2 LGMD) or autosomal dominant (Type 1 LGMD). These types are further divided into sub-types, which are classified using letters and numbers that indicate which gene is mutated and/or which protein is missing or deficient. Often, complex testing needs to be carried out to identify the exact genetic cause of LGMD in an individual; in some cases a precise genetic diagnosis might be reached over a long period of time or may not be possible.

What are the signs and symptoms of limb-girdle muscular dystrophy?

The most common clinical features of LGMD are progressive weakness and the degeneration of muscles mainly involving the shoulder girdle, the pelvic girdle, or both. Distal muscle (away from the core of the body) strength is usually preserved, even in the later stages of the disease, but distal muscle weakness can be an early or prominent feature in some LGMD subtypes. Often, people with LGMD first notice a problem when they begin to walk with a ‘waddling’ gait because of weakness in the hip and leg muscles. They may have trouble getting out of chairs, rising from a sitting position, or climbing stairs. The involvement of shoulder and arm muscles can lead to difficulty in raising arms above the head, and in lifting objects. In some types of LGMD, the heart and breathing muscles may be involved, therefore, regular checks may be needed to identify and treat if necessary.

How does the disease progress?

LGMD is a progressive disease, and muscles continue to get weaker throughout a person’s lifetime. However, LGMD presents and progresses differently depending on age, sub-type, heart and respiratory function, and severity.

As the condition progresses, people can have problems with walking and may need to use a wheelchair as weakness in the pelvic girdle and upper legs can cause frequent falls. Assistive devices, such as a cane or a long-handled reacher, can also make things easier as weakness progresses.

Primary Sidebar

  • Resources and Support
  • Disease Information
    • Neuromuscular Disease Information
    • Becker muscular dystrophy
    • Charcot-Marie-Tooth
    • Congenital muscular dystrophy
    • Congenital myasthenic syndromes
    • Duchenne muscular dystrophy
    • Facioscapulohumeral muscular dystrophy
    • GNE myopathy
    • Limb girdle muscular dystrophy
    • Myotonic dystrophy
    • Myotubular and centronuclear myopathies
    • Spinal muscular atrophy
  • Research Overview
    • Research Overview
    • Gene Therapy Research
    • DMD
      • DMD
      • Gene Therapy for DMD
      • Mutation Specific Approaches
      • Drug Therapy
        • Anti Inflammatory Drugs
        • Treating Fibrosis and Oxidative Stress
        • Ways to Improve Muscle Quality and Strenghth
        • Drugs to Bloodflow to Muscle
        • Drugs to Upregulate Utrophin
      • Cell Therapy
  • Standards of Care & Family Guides
    • Care Guides
    • BMD Care
    • CM Care
    • CMD Care
    • DM Care
    • DMD Care
    • FSHD Care
    • LGMD Care
    • SMA Care
  • Standard Operating Procedures (SOPs)
    • SOP Library
    • MDX Mouse (DMD)
    • GRMD Dog (DMD)
    • CMD Mouse (CMD)
    • SMA Mouse (SMA)
    • SOP Archive
      • MDX mouse (DMD) Archive
      • SMA mouse (SMA) Archive
      • Mouse model (DMD) Archive
  • Social and Ethical issues
    • Social and Ethical Issues
    • Concerns Over Stem Cell Therapy for SMA Type 1 Children
    • Early Access to Medicines in Development
    • Ethical Questions

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter Sign Up

Sign up to our monthly newsletter

 
ISO 27001 Accreditation Logo

Connect

info@treat-nmd.com
TREAT NMD © 2025
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
    • The Global Registry Network
      • Members of the Registry Network
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
    • Education
      • Masterclasses and Events
      • Digital Resources
      • Endorsement of External Programmes
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • BMD Care
      • FSHD Care
      • SMA Care
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us